Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rogaratinib versus chemotherapy in FGFR-positive advanced or metastatic urothelial carcinoma after platinum therapy
2016-004340-11Phase 2Unknown
- Sponsor
- Bayer
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rogaratinib in transitional cell carcinoma (TCC) (2 arms), sponsored by Bayer. Primary endpoint: Overall survival. Status: unknown.
02
Drugs
rogaratinib
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2016-004340-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004340-11.